Active substance
Cabergoline
- SFDA 12
- US FDA 11
- Health Canada 3
- US price lines 1
- NHS prices 3
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Bergo | 0.5 mg | Tablet · Oral use | 8 Bottle | SAR 87.60 | Generic · Prescription | JORDAN RIVER PHARMACEUTICAL INDUSTRIES | Valid |
| Bergo | 0.5 mg | Tablet · Oral use | 2 Bottle | SAR 32.15 | Generic · Prescription | JORDAN RIVER PHARMACEUTICAL INDUSTRIES | Valid |
| DOSTINEX 0.5MG TABLET | 0.5 mg | Tablet · Oral use | 8 Bottle | SAR 132.80 | NCE · Prescription | PFIZER | Valid |
| DOSTINEX 0.5MG TABLET | 0.5 mg | Tablet · Oral use | 2 Bottle | SAR 41.40 | NCE · Prescription | PFIZER | Valid |
| Dexorolin | 0.5 mg | Tablet · Oral use | 2 Bottle | SAR 35.20 | Generic · Prescription | Med City Pharma | Valid |
| Dexorolin | 0.5 mg | Tablet · Oral use | 8 Bottle | SAR 112.90 | Generic · Prescription | Med City Pharma | Valid |
| Lovista | 0.5 mg | Tablet · Oral use | 2 Jar | SAR 36.15 | Generic · Prescription | DAR ALDAWA | Valid |
| Lovista | 0.5 mg | Tablet · Oral use | 8 Jar | SAR 117.05 | Generic · Prescription | DAR ALDAWA | Valid |
| NOSTIFIX 0.5 mg TABLET | 0.5 mg | Tablet · Oral use | 8 Blister | SAR 119.50 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| NOSTIFIX 0.5 mg TABLET | 0.5 mg | Tablet · Oral use | 2 Blister | SAR 37.25 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Stronyx | 0.5 mg | Tablet · Oral use | 8 Blister | SAR 111.20 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
| Stronyx | 0.5 mg | Tablet · Oral use | 2 Blister | SAR 34.35 | Generic · Prescription | MS Pharma Saudi (MSPS) | Valid |
Indications — CHI Daman Drug Formulary
ACROMEGALY; CUSHING SYNDROME; HYPERPROLACTINEMIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CABERGOLINE | 0.5MG | tablet · oral | STRIDES PHARMA INTL | Prescription | 29 Dec 2005 |
| CABERGOLINE | 0.5MG | tablet · oral | IVAX SUB TEVA PHARMS | Prescription | 7 Mar 2007 |
| CABERGOLINE | 0.5MG | tablet · oral | INGENUS PHARMS LLC | Prescription | 1 Aug 2018 |
| CABERGOLINE | 0.5MG | tablet · oral | AMNEAL | Prescription | 25 Jun 2024 |
| CABERGOLINE | 0.5MG | tablet · oral | SOMERSET THERAPS LLC | Prescription | 9 Sep 2024 |
| CABERGOLINE | 0.5MG | tablet · oral | RENATA | Prescription | 15 Jun 2026 |
| DOSTINEX | 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | PFIZER | Discontinued | 23 Dec 1996 |
| CABERGOLINE | 0.5MG | tablet · oral | IMPAX LABS INC | Discontinued | 3 Jul 2007 |
| CABERGOLINE | 0.5MG | tablet · oral | ACTAVIS LABS FL INC | Discontinued | 21 Apr 2008 |
| CABERGOLINE | 0.5MG | tablet · oral | APOTEX CORP | Discontinued | 8 Mar 2013 |
| CABERGOLINE | 0.5MG | tablet · oral | PHARMOBEDIENT | Discontinued | 2 Dec 2013 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-CABERGOLINE | 02455897 | 0.5 MG | TABLET · ORAL | APOTEX INC |
| DOSTINEX | 02242471 | 0.5 MG | TABLET · ORAL | PFIZER CANADA ULC |
| JAMP CABERGOLINE | 02549611 | 0.5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CABERGOLINE 0.5 MG TABLET | $1.29524 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Cabergoline 1mg tablets | £60.75 | 20 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cabergoline 2mg tablets | £112.13 | 20 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Cabergoline 500microgram tablets | £9.87 | 8 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 18.8. Medicines for disorders of the pituitary hormone system · core
Other specified benign neoplasm of endocrine glands
Oral > Solid > tablet: 0.5 mg; 1 mg
Safety signals and safety-related labeling changes
- US FDA 21 Apr 2025 DOSTINEX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.